100 related articles for article (PubMed ID: 22324879)
1. CD133+ cells as a therapeutic target for kidney diseases.
Bussolati B; Collino F; Camussi G
Expert Opin Ther Targets; 2012 Feb; 16(2):157-65. PubMed ID: 22324879
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia modulates the undifferentiated phenotype of human renal inner medullary CD133+ progenitors through Oct4/miR-145 balance.
Bussolati B; Moggio A; Collino F; Aghemo G; D'Armento G; Grange C; Camussi G
Am J Physiol Renal Physiol; 2012 Jan; 302(1):F116-28. PubMed ID: 21900452
[TBL] [Abstract][Full Text] [Related]
3. Only anti-CD133 antibodies recognizing the CD133/1 or the CD133/2 epitopes can identify human renal progenitors.
Angelotti ML; Lazzeri E; Lasagni L; Romagnani P
Kidney Int; 2010 Sep; 78(6):620-1; author reply 621. PubMed ID: 20805819
[No Abstract] [Full Text] [Related]
4. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation.
Kemper K; Sprick MR; de Bree M; Scopelliti A; Vermeulen L; Hoek M; Zeilstra J; Pals ST; Mehmet H; Stassi G; Medema JP
Cancer Res; 2010 Jan; 70(2):719-29. PubMed ID: 20068153
[TBL] [Abstract][Full Text] [Related]
5. Two novel monoclonal antibodies against human CD133-2: distinct epitopes and agonist activity to enhance growth of CD133 expression cells in vitro.
Wang J; Li F; Zhang G; Chen Y; Hu Y; Chen X; Lu B; Zhang X
Hybridoma (Larchmt); 2010 Jun; 29(3):241-9. PubMed ID: 20569000
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel monoclonal antibody recognizing CD133.
Swaminathan SK; Olin MR; Forster CL; Cruz KS; Panyam J; Ohlfest JR
J Immunol Methods; 2010 Sep; 361(1-2):110-5. PubMed ID: 20674577
[TBL] [Abstract][Full Text] [Related]
7. CD133+ renal progenitor cells contribute to tumor angiogenesis.
Bruno S; Bussolati B; Grange C; Collino F; Graziano ME; Ferrando U; Camussi G
Am J Pathol; 2006 Dec; 169(6):2223-35. PubMed ID: 17148683
[TBL] [Abstract][Full Text] [Related]
8. CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells.
Lehnus KS; Donovan LK; Huang X; Zhao N; Warr TJ; Pilkington GJ; An Q
Int J Oncol; 2013 Mar; 42(3):1011-7. PubMed ID: 23340741
[TBL] [Abstract][Full Text] [Related]
9. [Influence and distribution of CD133 and CD34 antigen expression in proximal tubule epithelial cells during ischemia/reperfusion injury in rats].
Chen FM; Jiang XN; Shi JQ; Yan B; Ren DS; Gu J; Li DB; Zhang Y; Shen J; Liang J; Wang Y
Zhonghua Yi Xue Za Zhi; 2010 Nov; 90(40):2864-8. PubMed ID: 21162801
[TBL] [Abstract][Full Text] [Related]
10. Insight into the complex regulation of CD133 in glioma.
Campos B; Herold-Mende CC
Int J Cancer; 2011 Feb; 128(3):501-10. PubMed ID: 20853315
[TBL] [Abstract][Full Text] [Related]
11. Cystogenic potential of CD133+ progenitor cells of human polycystic kidneys.
Carvalhosa R; Deambrosis I; Carrera P; Pasquino C; Rigo F; Ferrari M; Lasaponara F; Ranghino A; Biancone L; Segoloni G; Bussolati B; Camussi G
J Pathol; 2011 Sep; 225(1):129-41. PubMed ID: 21706482
[TBL] [Abstract][Full Text] [Related]
12. Photochemical internalization (PCI) of immunotoxins targeting CD133 is specific and highly potent at femtomolar levels in cells with cancer stem cell properties.
Bostad M; Berg K; Høgset A; Skarpen E; Stenmark H; Selbo PK
J Control Release; 2013 Jun; 168(3):317-26. PubMed ID: 23567040
[TBL] [Abstract][Full Text] [Related]
13. RNA aptamers targeting cancer stem cell marker CD133.
Shigdar S; Qiao L; Zhou SF; Xiang D; Wang T; Li Y; Lim LY; Kong L; Li L; Duan W
Cancer Lett; 2013 Mar; 330(1):84-95. PubMed ID: 23196060
[TBL] [Abstract][Full Text] [Related]
14. CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope.
Mak AB; Blakely KM; Williams RA; Penttilä PA; Shukalyuk AI; Osman KT; Kasimer D; Ketela T; Moffat J
J Biol Chem; 2011 Nov; 286(47):41046-56. PubMed ID: 21937449
[TBL] [Abstract][Full Text] [Related]
15. [The CD133 polyclonal antibody generation and cancer stem cells identification].
Tian JL; Cai PL; Xia XQ; Li FH; Wang DH; Chen MN
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 May; 42(3):422-6. PubMed ID: 21827013
[TBL] [Abstract][Full Text] [Related]
16. R2: identification of renal potential progenitor/stem cells that participate in the renal regeneration processes of kidney allograft fibrosis.
Bao J; Tu Z; Sun H; Luo G; Yang L; Song J; Qin M; Shi Y; Bu H; Li Y
Nephrology (Carlton); 2008 Dec; 13(6):500-7. PubMed ID: 18363645
[TBL] [Abstract][Full Text] [Related]
17. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo.
Huang J; Li C; Wang Y; Lv H; Guo Y; Dai H; Wicha MS; Chang AE; Li Q
Clin Immunol; 2013 Oct; 149(1):156-68. PubMed ID: 23994769
[TBL] [Abstract][Full Text] [Related]
18. Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients.
Feller N; van der Pol MA; Waaijman T; Weijers GW; Westra G; Ossenkoppele GJ; Schuurhuis GJ
Clin Cancer Res; 2005 Jul; 11(13):4793-801. PubMed ID: 16000576
[TBL] [Abstract][Full Text] [Related]
19. Effects of CXCR1 and CXCR2 inhibition on expansion and differentiation of umbilical cord blood CD133(+) cells into megakaryocyte progenitor cells.
Adeli EK; Abolghasemi H; Ebtekar M; Pourpak Z; Kheirandish M
Cytokine; 2011 Aug; 55(2):181-7. PubMed ID: 21555225
[TBL] [Abstract][Full Text] [Related]
20. CD133 is essential for glioblastoma stem cell maintenance.
Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
